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Abstract 
Review on SOCS2, with data on DNA, on the protein 
encoded, and where the gene is implicated. 
Keywords: SOCS2; proteasome; immune cell 
differentiation; neuronal development; 
inflammation; cancer; diabetes 
Identity 
Other names: CIS-2, CIS2, Cish2, SOCS-2, SSI-2, 
SSI2, STATI2 
HGNC (Hugo): SOCS2 
Location: 12q21.3-q23 (Yandava et al., 1999). Plus 
strand. 
DNA/RNA 
Description 
NCBI Reference Sequence: NC_000012.12; Coding 
positions from 93,966,674 to 93,968,952 (length: 
2,279 bp). Mouse SOCS2 gene is composed of 3 
exons and 2 introns (Metcalf et al., 2000). Human 
SOCS-2 comprises 3 exons spanning approximately 
6,38 kb of genomic DNA. 
Transcription 
2888 bp mRNA. There are 6 transcript variants. 
Transcript variant 5 is the largest and is cited here. 
The variants differ in their 5' UTR. All variants 
encode the same protein. 
Protein 
Description 
Reference sequence for SOCS2 protein: 
NP_001257399.1. SOCS2 contains 198 amino acid 
residues with a molecular weight of 22172 Da. 
SOCS2 belongs to the SOCS box family. SOCS2 
contains a C terminal SOCS box (residue 151-197) 
for ElonginB,C/Cullin5/Rbx2 interaction. The 
unstructured N-terminal region (residue 1-47) and 
the SH2 domain (residue 48-156) is implicated in 
substrate interaction. The SH2 domain is known to 
interact with conserved phosphotyrosine residues on 
target proteins imparting substrate specificity to 
SOCS box proteins. 
Expression 
SOCS mRNA and protein levels are constitutively 
low in unstimulated cells, but their expression is 
rapidly induced upon cytokine stimulation, thereby 
creating a negative feedback loop. Although 
constitutively expressed SOCS2 mRNA has been 
detected in several tissues and cell types, its 
expression is, in general, induced by stimulation 
with different cytokines and hormones (Rico-
Bautista et al., 2006). SOCS2 promoter analysis 
indicates the presence of AhR and STAT5 binding 
sites that confer responsiveness to dioxin (Boverhof 
et al., 2004) and GH (Vidal et al., 2006), 
respectively. 
SOCS2 (suppressor of cytokine signaling 2) Paul I, et al. 
 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2016; 20(6) 342 
 
 
Diagram representing the structure of SOCS proteins. At least eight proteins belonging to the SOCS family of proteins are shown 
(upper panel). They are characterized by the presence of an SH2 central domain and the SOCS box domain at the C-terminus. A 
small domain called kinase inhibitory region (KIR), only found in SOCS1 and SOCS3, is shown as a small box at the N-
terminal region. SOCS proteins can interact with phosphotyrosine phosphorylated proteins through their SH2 domain and with 
Elongin BC through their SOCS box domain. Other proteins containing a SOCS box domain but lacking a SH2 domain are also 
shown (lower panel). Adapted from Elliot and Johnston (Elliott and Johnston, 2004) with modifications. 
 
Localisation 
Intracellular, cytoplasm. SOCS2 can be located in 
the nuclear compartment when overexpressed in cell 
cultures. 
Function 
The function of SOCS proteins rely, on one hand, in 
their ability to bind tyrosine phosphorylated proteins 
through their SH2 domains and, on the other hand, 
to bind Elongins B/C through their SOCS box 
domains which in turn engages with the 
Cullin5/Rbx2 complex to assemble an E3 ubiquitin 
ligase.  
SOCS family proteins form part of a classical 
negative feedback system that regulates cytokine 
signal transduction (Rico-Bautista et al., 2006).  
Being a substrate recognition module for 
Cullin5/Rbx2 E3 ligase complex, SOCS2 is involved 
in regulating protein turnover by targeting proteins 
for proteasome-mediated degradation. SOCS2 binds 
and promote the ubiquitination of the Growth 
Hormone receptor (GHR) controlling GHR content 
in different tissues (Metcalf et al., 2000; Vesterlund 
et al., 2011).  
Through the negative regulation of GHR signaling, 
SOCS2 exerts multiple actions in growth and 
metabolisms (Greenhalgh et al., 2005; Zadjali et al., 
2012).  
SOCS2 is also a critical regulator of inflammatory 
responses and immune cell differentiation (Machado 
et al., 2006; Hu et al., 2009a). Recently, SOCS2 is 
being implicated in the progression of multiple 
human cancers (Schultheis et al., 2002; Harris et al., 
2006; Newton et al., 2010; Iglesias-Gato et al., 
2014). 
Homology 
HomoloGene (NCBI) Genes identified as putative 
homologs: NP_003868.1 SOCS2, H.sapiens; 
XP_001139989.1 SOCS2, P.troglodytes; 
XP_002798772.1 SOCS2, M.mulatta; 
XP_005629280.1 SOCS2, C.lupus; NP_803489.1 
SOCS2, B.taurus; NP_001162126.1 Socs2, 
M.musculus; NP_478115.1 Socs2, R.norvegicus; 
NP_989871.1 SOCS2, G.gallus; NP_001120898.1 
socs2, X.tropicalis; NP_001108022.1 socs2, D.rerio 
Mutations 
Note 
There are 8 SNPs in coding regions of human 
SOCS2 which result in missense protein residues 
(NCBI dbSNP).  
Homozygous null mice display gigantism (Metcalf 
et al., 2000), impaired innate immune cell 
differentiation and hypersensitivity to infections 
(Baetz et al., 2004; Yoshimura et al., 2005; 
Yoshimura et al., 2007). Homozygous null mice also 
display altered metabolic and inflammatory response 
to high fat feeding (Zadjali et al., 2012;). SNP: 
increasing the risk of type 2 diabetes (Kato et al., 
2006) 
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Implicated in 
Neural development 
Note 
SOCS2 plays a critical role in neuronal development, 
growth, and stem cell differentiation (Turnley et al., 
2002). 
Inflammation 
Note 
SOCS2 deficient dendritic cells and macrophages 
are hyper-responsive to microbial stimulation. 
SOCS2 deficient animals have uncontrolled 
production of inflammatory cytokines (IL-12, 
IFNγand TNFα ) and succumb to endotoxic shock, 
polymicrobial sepsis and other microbial infections 
(Esper et al., 2012).  
SOCS2 plays a central role in differentiation and 
maturation of innate immune cells. Specifically, 
SOCS2 promotes generation of regulatory dendritic 
cells and macrophages (Novak et al., 1999; Jackson 
et al., 2004; Hu et al., 2012) and Treg population 
(Knosp et al., 2013).  
Conversely, SOCS2 inhibits Th2 differentiation 
(Knosp et al., 2011). 
Upon induced inflammatory challenge, absence of 
SOCS2 has been shown to render multiple immune 
cell types incapable of mounting anti-inflammatory 
responses.  
Under resting conditions, SOCS2 null animals also 
display a population-bias towards a pro-
inflammatory phenotype (Machado et al., 2006; Lee 
et al., 2010; Knosp et al., 2011; Posselt et al., 2011; 
Hu et al., 2012).  
SOCS2 is known to inhibit TGFβ, IL-4, IL-5, IL-10, 
IL-13 and IFNγ signaling (Knosp et al., 2011, Knosp 
et al., 2013).  
In general, SOCS2 inhibits expression/secretion of 
pro-inflammatory cytokines and promotes 
generation of regulatory phenotype (anti-
inflammatory) of immune cells. SOCS2 is thought to 
function in both MyD88 dependent and independent 
TLR4 signaling pathways because its 
downregulation negatively affects SAPK/JNK, p38 
MAPK, ERK and NFkB signaling (Hu et al., 2009b). 
Being an E3 ligase, SOCS2 regulates a number of 
proteins highly implicated in regulation of immune 
responses such as FoxP3 (Knosp et al., 2013) and 
TRAF6 (McBerry et al., 2012). SOCS2 also 
accelerates degradation of other members of the 
SOCS family such as SOCS1 and SOCS3 thus 
further impinging on downstream STAT signaling 
(Piessevaux et al., 2006; Tannahill et al., 2005).  In 
turn, SOCS2 gene itself is under regulation of 
various inflammatory signals (e.g., LPS, dioxins, 
LipoxinA4) (Machado et al., 2006; Hu et al., 2009b, 
2012) and cytokines (e.g.,IL-4, IL-10, IFNβ, IFNγ) 
(Knosp et al., 2011; Posselt et al., 2011). 
Breast cancer 
Note 
SOCS2 expression inversely correlates with 
histological grades and is a positive prognostic factor 
(Farabegoli et al., 2005; Haffner et al., 2007). 
SOCS2 expression is induced by estrogen receptor 
(ER) activity. Estrogen treatment activates ER which 
in turn upregulates miR-191 which through 
downregulation of SATB1, a global chromatic 
remodeller, enhances SOCS2 transcription (Nagpal 
et al., 2013). Upregulation of SOCS2 upon estrogen 
administration antagonizes growth hormone action 
mediated through JAK2/STAT3 and STAT5 (Leung 
et al., 2003). 
Colon cancer 
Note 
Both heterozygous and homozygous deletions of 
SOCS2 promoted spontaneous tumorigenesis in 
ApcMin/+ mice model of colorectal cancer. This is 
accompanied with a dramatic increase in AP-1 DNA 
binding (Newton et al., 2010). Acromegalic patients 
are prone to colonic polyp formation. These patients 
with hyperplastic polyps have increased SOCS2 
transcripts (Bogazzi et al., 2009). 
Myeloproliferative disorder 
Note 
SOCS2 gene is also hypermethylated in 
myeloproliferative disorders (Zhou et al., 2009; 
Zhang et al., 2013). SOCS2 is an important negative 
regulator of a constitutive active mutant of JAK2 
(JAK2 V617F) (Etienne et al., 2007). 
Prostate cancer 
Note 
SOCS2 is upregulated at both mRNA and protein 
levels in primary prostate cancer tissues relative to 
normal prostate. This upregulation is correlated to 
lower Gleason score, absence of metastasis and low 
PSA failure (Zhu et al., 2013). In contrast, SOCS2 
expression is downregulated in castration resistant 
prostate cancer. This is partly explained by the fact 
that SOCS2 is transcriptionally upregulated by 
androgen receptor and inhibits GH signaling in 
prostate (Iglesias-Gato et al., 2014). 
Other cancers 
Note 
SOCS2 gene is hypermethylated in melanoma and 
ovarian carcinoma (Marini et al., 2006; Liu et al., 
2008). Lower SOCS2 expressions are also correlated 
to higher grades of hepatocellular carcinoma (Qiu et 
al., 2013). 
Gigantism 
Note 
SOCS2 null mice are giants but not obese (Metcalf 
et al., 2000). SOCS2 deficient mice have growth and 
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metabolic characteristics that can be related to the 
enhanced GH actions (Rico-Bautista et al., 2005). 
On the other hand, the gigantic phenotype displayed 
by SOCS2 null mice is mechanistically different 
from that of human acromegalic patients as they do 
not exhibit increased circulating IGF-1 levels and 
seems to express reduced levels of GH (Greenhalgh 
2005 and Zadjali 2012). 
Disease 
Gigantism is a condition characterized by excessive 
growth, significantly above average. This is caused 
due to an overactivation of growth hormone 
signaling. 
Diabetes 
Note 
Genomic linkage analysis identified SOCS2 as a 
susceptibility gene for type 2 diabetes in a cohort of 
Japanese individuals. In the same study, adenovirus-
mediated expression of the SOCS2 gene in MIN6 
cells or isolated rat islets significantly suppressed 
glucose-stimulated insulin secretion (Kato et al., 
2006). Constitutive SOCS2 expression in mice 
pancreatic beta cells interferes with proinsulin 
processing and leads to decreased insulin secretion 
(Lebrun et al., 2010). In contrast, SOCS2 null mice 
does not exhibit obvious defects in pancreatic beta 
cell function. When challenged with high fat diet 
SOCS2 null mice are protected from hepatic 
steatosis but exhibit an exacerbated inflammatory 
response and a worsening of insulin sensitivity as 
compared to wild-type mice on a similar diet. 
Disease 
Diabetes is a condition characterized by high blood 
sugar levels. This is caused due to inadequate insulin 
production or insulin resistance. 
Osteoarthritis 
Note 
Analysis of SOCS2 null mice has revealed that the 
absence of SOCS2 induces a reduction in the 
trabecular and cortical volumetric bone mineral 
density (Lorentzon et al., 2005). SOCS2 induces the 
differentiation of C2C12 mesenchymal cells into 
myoblasts or osteoblasts (Ouyang et al., 2006). 
Disease 
Osteoarthritis is a condition characterized by 
mechanical degeneration of joints resulting in pain 
and restricted movement. This is caused due to 
hereditary and metabolic reasons. 
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